InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone
6/29/2010 8:52:18 AM
More...
|
InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting
6/18/2010 10:20:58 AM
More...
|
InteKrin Therapeutics Appoints Linda Higgins, PhD as President and Chief Executive Officer
5/10/2010 6:48:12 AM
More...
|
InteKrin Therapeutics Appoints Roman Skowronski, MD, PhD as Vice President of Clinical Development
4/23/2010 9:54:42 AM
More...
|
InteKrin Therapeutics' Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
2/8/2010 8:14:04 AM
More...
|
InteKrin Therapeutics to Present at the 28th Annual JP Morgan Healthcare Conference on Monday, January 11, 2010
1/11/2010 9:00:05 AM
More...
|
InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
9/30/2009 9:28:51 AM
More...
|
InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
9/30/2009 9:10:20 AM
More...
|
InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer
9/15/2009 8:38:45 AM
More...
|
InteKrin Therapeutics Announces Appointment of Geoffrey M. Parker as Chief Business Officer
7/13/2009 11:21:51 AM
More...
|
|